RAPT Therapeutics

Novel Anti-IgE Antibody LP-003 Shows Superior Efficacy Over Omalizumab in Chronic Spontaneous Urticaria Trial

3 months ago

• Longbio's LP-003 demonstrated superior improvement in UAS7 scores compared to Omalizumab at weeks 4 and 12 in Phase II trial for Chronic Spontaneous Urticaria treatment. • The novel long-acting anti-IgE antibody showed rapid symptom relief with a favorable safety profile and extended dosing interval of up to 8 weeks, potentially offering better treatment convenience. • Results position LP-003 as a potential best-in-class therapy in the growing CSU market, with comparable efficacy to barzolvolimab and plans for expansion into food allergy and asthma indications.

RAPT Therapeutics Initiates Phase 2a Trial of RPT193 for Moderate-to-Severe Asthma

5 months ago

• RAPT Therapeutics has commenced a Phase 2a clinical trial to assess RPT193, an oral, once-daily monotherapy, for treating moderate-to-severe asthma. • The trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of RPT193 over 14 weeks. • RPT193 selectively inhibits the migration of Th2 cells into inflamed tissues by blocking CCR4, making it a potential therapeutic option for Type 2-high asthma. • The primary endpoint is the proportion of patients who experience a loss of asthma control during the trial, with ICS and LABA being gradually tapered.

RAPT Therapeutics Licenses Novel Anti-IgE Antibody RPT904 for Global Development

5 months ago

• RAPT Therapeutics secures exclusive worldwide rights, excluding China, to develop and commercialize RPT904, a long-acting anti-IgE antibody. • Shanghai Jemincare Pharmaceutical will receive $35 million upfront, potential milestone payments up to $672.5 million, and royalties on future sales. • RAPT plans to initiate a Phase 2b clinical trial of RPT904 in food allergy in the second half of 2025, addressing a significant unmet need. • Jemincare is currently conducting Phase 2 trials in China for asthma and chronic spontaneous urticaria, with topline data expected in 2025 and 2026.

RAPT Therapeutics Discontinues Zelnecirnon Program Following FDA Feedback

6 months ago

• RAPT Therapeutics halts the development of zelnecirnon (RPT193) after receiving feedback from the FDA regarding safety concerns. • The decision follows a clinical hold placed on Phase 2 trials for asthma and atopic dermatitis due to a severe liver injury in one patient. • RAPT plans to advance next-generation CCR4 compounds with improved safety profiles and explore licensing opportunities for clinical-stage assets. • The company aims to identify a new candidate for inflammatory diseases in the first half of 2025, focusing on safer oral therapeutics.

RAPT Therapeutics' Zelnecirnon Trials Halted Due to Liver Failure; Iovance's Amtagvi Receives FDA Approval

a year ago

• RAPT Therapeutics' trials for zelnecirnon in atopic dermatitis and asthma were halted after a patient experienced liver failure, potentially linked to the drug. • The FDA granted accelerated approval to Iovance Biotherapeutics' Amtagvi (lifileucel) for treating advanced melanoma in patients previously treated with a PD-1 blocking antibody. • Moderna reaffirmed its 2024 product sales guidance of approximately $4 billion, driven by COVID-19 Vaccine Spikevax sales, and anticipates initial regulatory approvals for its RSV vaccine in the first half of 2024.

RAPT Therapeutics Announces Positive Results from Phase 1a/1b Clinical Trial of Zelnecirnon for Atopic Dermatitis

a year ago

RAPT Therapeutics has published promising results from its Phase 1a/1b clinical trial of zelnecirnon (RPT193) for treating atopic dermatitis, showing significant clinical and molecular improvements with no serious adverse events reported.